Slide 1: Delivering Shareholder Value
Delivering Shareholder Value Aradhana Sarin, CFO Investor Day • 2024
Slide 2: Forward looking statements
Forward looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Delivering on shareholder value
Delivering on shareholder value Index Total shareholder return % 650 +535% 600 550 500 450 400 350 300 +198% 250 200 +121% 150 100 12 13 14 23 5 6 7 8 9 0 1 2 3 01 01 01 01 01 02 02 02 02 20 20 20 20 /2 /2 /2 /2 /2 /2 /2 /2 /2 1/ 0/ 1/ 1/ 30 31 31 30 31 30 31 28 31 /3 /3 /3 /3 9/ 8/ 7/ 6/ 5/ 4/ 3/ 2
Slide 4: Ambition – $80bn Total Revenue by 2030 and sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 and sustained 2030+ growth Beyond 2030 Illustrative only, not to scale ADCs and Radioconjugates Cell therapy and T-cell engagers Launching key NMEs $80bn Gene therapy AZD0120 rilvegostomig AZD0486 saruparib Next-generation IO bispecifics camizestrant volrustomi
Slide 5: Strong growth potential 2030+
Strong growth potential 2030+ Multiple NMEs with $5bn+ Peak Year Revenue potential launching by 20301 NMEs currently in Phase III NMEs currently in Phase I/II AZN ADCs*,4 camizestrant volrustomig multiple | solid tumours, haem ngSERD | breast cancer PD-1/CTLA-4 | lung, HNSCC, others AZD0486 CD19/CD3
Slide 6: Significant growth in blockbuster portfolio by 2030
Significant growth in blockbuster portfolio by 2030 Existing blockbuster medicines1 25+ potential blockbusters by 20302 + AZN ADCs AZD0120 AZD0486 camizestrant Dato-DXd rilvegostomig saruparib volrustomig balcinrenone/ baxdrostat zibotentan/ tozorakimab dapagliflozin franchise dapagliflozin IVX-A12
Slide 7: Operational model drives organisation productivity
Operational model drives organisation productivity • Portfolio prioritisation based on • Rigorous technical reviews scientific merit and risk- adjusted NPV Focus on Smart clinical • External advisory boards • Robust forecasting value development • Biomarker and patient creation segmentation • Early
Slide 8: Continued focus on cash conversion
Continued focus on cash conversion Net cash inflow from operating activities Operating cash flow as % of Total Revenue $m 12,000 10,000 8,000 6,000 4,000 Vaxzevria impact 2,000 0 2020 2021 2022 2023 Increasing cash generation Improving cash conversion 8 Acronym definitions can be found in Glossary.
Slide 9: Capital allocation priorities remain unchanged
Capital allocation priorities remain unchanged Reinvestment Strong in our business investment-grade 1.9x (incl. CapEx) credit rating Net Debt/Adjusted EBITDA1 CapEx investment to support revenue growth +$0.20 Business Progressive +$0.10 2024 development dividend policy Value-enhancing business 2022
Slide 10: CapEx investments to support future growth
CapEx investments to support future growth 2024 CapEx investments – Future CapEx – investment to building manufacturing capacity support top-line growth Inhaled facility (Qingdao, China) ADC manufacturing (Singapore) API facility (Dublin, Ireland) Cell therapy capacity for ex-US markets Cell therapy
Slide 11: On track to achieve mid-30s% Core operating margin by 2026
On track to achieve mid-30s% Core operating margin by 2026 $m % 50,000 36% 34% 45,000 Core R&D to remain at low-20s% of Total Revenue 32% 40,000 30% 35,000 28% Core SG&A % of Total Revenue to decrease 26% 30,000 • Greater speciality mix • LOEs enabling resource 24% • LCMs leveraging existing redeplo
Slide 12: Core operating margin beyond 2026
Core operating margin beyond 2026 Investment in innovation to drive growth to 2030 and beyond Investing in innovation to deliver 2030+ growth • Commercial launches in large market opportunities ― Large new potential opportunities in primary care ― Novel combinations and specialty areas ― New indicat
Slide 13: AstraZeneca set to deliver continued shareholder value
AstraZeneca set to deliver continued shareholder value • Deliver $80bn in Total Revenue by 2030 • Ambition to launch 20 NMEs by 2030 Therapy • Invest to drive next waves of growth 2030+ • 25+ potential blockbusters by 2030 Financial Area • Mid-30s% Core operating margin by 2026 • Leverage depth and
Slide 14: Q&A session
Q&A session Pascal Soriot Aradhana Sarin Dave Fredrickson C EO , AS T RAZEN EC A C F O , AS T RAZEN EC A EVP, O N C O L O GY Cristian Massacesi Sunil Verma Susan Galbraith C H IEF MEDIC AL O F F IC ER AN D EVP, O N C O L O GY R& D S VP, GL O B AL H EAD O F O N C O L O GY C H IEF O N C O L O GY , MED
Slide 15: Summary and Close
Summary and Close Pascal Soriot, CEO Investor Day • 2024
Slide 16: Concluding remarks
1 New ambition to deliver $80bn in Total Revenue by 2030, with sustained growth 2030+ Mid-30s% Core operating margin by 2026. Beyond 2026, Core 2 operating margin will be influenced by portfolio evolution and Concluding remarks the Company will target at least mid-30s% AstraZeneca is a unique 3 Glob
Slide 17: Appendix
Appendix 17 Investor Day • 2024
Slide 18: Glossary – 1 of 2
Glossary – 1 of 2 1L, 2L, 3L first-, second-, third-line CLL chronic lymphocytic leukaemia GLP-1/glu glucagon-like peptide 1 receptor/glucagon dual peptide agonist 6MWT 6-minute walk test cm centimetre GLP-1RA glucagon-like peptide 1 receptor agonist AAV adeno-associated virus CM cardiomyopathy gMG
Slide 19: Glossary – 2 of 2
Glossary – 2 of 2 K+ potassium NST neoadjuvant systemic treatment RSV respiratory syncytial virus KCCQ Kansas City Cardiomyopathy Questionnaire NT-proBNP N-terminal pro-B-type natriuretic peptide s. asthma severe asthma LA amylin long-acting amylin NYHA New York Heart Association s.c. subcutaneous L